Cytokinetics, Incorporated
CYTK
Pozycja w akcjach
#2305
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Cena akcji
$62.08
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$8.63B
Zmiana (1 dzień)
0.21%
Zmiana (1 rok)
4.60%
Kraj
US
Handel Cytokinetics, Incorporated (CYTK)
Kategoria
Healthcare
Liczba akcji w obrocie dla Cytokinetics, Incorporated (CYTK)
Liczba akcji w obrocie na dzień June 2026: 132.09M
Zgodnie z najnowszymi raportami finansowymi i ceną akcji Cytokinetics, Incorporated, aktualna liczba akcji w obrocie to 132.09M. Na koniec December 2023 firma posiadała 96.52M akcji w obrocie. Liczba akcji w obrocie jest zwykle kształtowana przez podziały akcji i skupy akcji.
Historia liczby akcji w obrocie dla Cytokinetics, Incorporated (CYTK) od 2000 do 2026
Akcje w obrocie na koniec każdego roku
| Rok | Akcje w obrocie | Zmień |
|---|---|---|
| 2026 (TTM) | 132.09M | 17.96% |
| 2024 | 111.98M | 16.01% |
| 2023 | 96.52M | 7.46% |
| 2022 | 89.83M | 16.83% |
| 2021 | 76.89M | 19.16% |
| 2020 | 64.52M | 12.07% |
| 2019 | 57.58M | 5.80% |
| 2018 | 54.42M | 10.15% |
| 2017 | 49.40M | 23.69% |
| 2016 | 39.94M | 3.32% |
| 2015 | 38.66M | 8.27% |
| 2014 | 35.71M | 30.92% |
| 2013 | 27.28M | 50.63% |
| 2012 | 18.11M | 53.45% |
| 2011 | 11.80M | 10.34% |
| 2010 | 10.69M | 11.81% |
| 2009 | 9.57M | 16.19% |
| 2008 | 8.23M | 3.79% |
| 2007 | 7.93M | 29.96% |
| 2006 | 6.10M | 28.12% |
| 2005 | 4.76M | 44.51% |
| 2004 | 3.30M | 935.01% |
| 2003 | 318.50K | 9.70% |
| 2002 | 290.33K | 22.69% |
| 2001 | 236.64K | 47.10% |
| 2000 | 160.87K | 0.00% |
Akcje w obrocie dla podobnych firm lub konkurentów
| Firma | Akcje w obrocie | Różnica | Kraj |
|---|---|---|---|
| 253.90M | 92.22% |
US
|
|
| 396.00M | 199.80% |
US
|
|
| 478.91M | 262.58% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -52.92% |
NL
|
